Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc

On January 23, 2024, Jeffrey Albers, a director at Kymera Therapeutics Inc (NASDAQ:KYMR), executed a sale of 10,000 shares of the company's stock, as reported in a recent SEC Filing.

Related Keywords

,Kymera Therapeutics Inc Is Fairly ,Kymera Therapeutics Inc ,Gurufocus Value ,Fairly Valued ,Biotechnology Company ,Jeffrey Albers ,